Form 4: EBS CFO Lindahl Sells Shares for Tax Obligations

Emergent BioSolutions' CFO, Richard S. Lindahl, disposed of 683 common shares to cover tax liabilities related to restricted stock unit vesting.

Summary

• Richard S. Lindahl, EVP, Chief Financial Officer of Emergent BioSolutions Inc. (EBS), reported a transaction on March 1, 2026.
• The transaction involved the disposition of 683 shares of common stock.
• These shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units.
• The shares were valued at $8.15 per share for the purpose of this transaction.
• Following this transaction, Mr. Lindahl directly beneficially owns 239,017 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard tax-related disposition of shares by an insider, which is a common occurrence and not indicative of a change in company fundamentals or insider sentiment.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard regulatory disclosures for insider transactions. This specific filing details a routine tax-related disposition of shares, which is common for executives receiving equity compensation and typically does not reflect a change in management's outlook on the company's prospects.

Key Dates

Recommendation

This Form 4 filing details a routine disposition of shares by a company executive to cover tax obligations related to restricted stock unit vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company or its future prospects. Therefore, it does not provide new information that would alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Emergent BioSolutions, EBS, Richard S. Lindahl, CFO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting